Snowball logo
logo
HXB2

AIM IMMUNOTECH INC.

€6.10€0.00  (0%)
Estimate
EPS
-0.21
Beta
0.322
About the company
Ticker
HXB2
ISIN
US00901B1052
Country
United States of America
Sector (GICS)
Healthcare
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Frequently asked questions

What sector does AIM IMMUNOTECH INC. (HXB2) operate in?

AIM IMMUNOTECH INC. belongs to the Healthcare sector and operates in the Biotechnology industry.

What is AIM IMMUNOTECH INC. (HXB2) current stock price?

As of the latest data, AIM IMMUNOTECH INC. stock price is €6.10, with a previous close of €6.10.

What is AIM IMMUNOTECH INC. (HXB2) current market capitalization?

AIM IMMUNOTECH INC. market cap is approximately 466.19 million.

What is AIM IMMUNOTECH INC. (HXB2) Earnings Per Share (EPS)?

The trailing EPS is -€0.21.

Does AIM IMMUNOTECH INC. (HXB2) pay dividends?

No. AIM IMMUNOTECH INC. does not pay a dividend.

What is AIM IMMUNOTECH INC. (HXB2) beta (volatility) score?

AIM IMMUNOTECH INC. has a beta of 0.322, indicating lower volatility than the overall market.